title: Should we suppress the antigenic stimulus in IPSID for lifelong?
authors.forename: A F
authors.initials: AF
authors.lastname: Celik
authors.forename: G E
authors.initials: GE
authors.lastname: Pamuk
authors.forename: O N
authors.initials: ON
authors.lastname: Pamuk
authors.forename: H
authors.initials: H
authors.lastname: Uzunismail
authors.forename: E
authors.initials: E
authors.lastname: Oktay
authors.forename: G
authors.initials: G
authors.lastname: Doğusoy
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007161:Immunoproliferative Small Intestinal Disease / Q000188:drug therapy* / Q000276:immunology*; D011241:Prednisone / Q000008:administration & dosage; D013752:Tetracycline / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013752:Tetracycline; D011241:Prednisone